Clinical and Hormonal Response To Bromocriptin (CB-154) in the Galactorrhea Syndromes

ABSTRACT Nine female patients with galactorrhea were selected for treatment with Bromocriptin® (CB-154), a specific inhibitor of prolactin secretion. Elevated plasma prolactin (hPRL) was found in 7 of these cases, whereas 2 exhibited values within normal limits. LHRH (100 μg) stimulation elicited plasma LH/FSH increases in 6 of the women who were amenorrheic prior to therapy, indicating a suprasellar cause for the patients' failure to cycle. After TRH (250 μg) stimulation, 5 women out of 6 exhibited a blunted hPRL response and 4 of them failed to show any elevations after administration of chlorpromazine. It was only in one patient who exhibited basal hPRL within the normal range, that an average response to TRH was elicited. The possible mechanisms explaining the low levels of pituitary stimulation obtained are discussed. Treatment with CB-154 (3–5 mg/day) induced a fall in serum hPRL accompanied by cessation of milk secretion in 8 patients. Menses were restored in 7 amenorrheic women and corpora lutea f...